Metsera announces positive phase 1 data of first-in-class once-monthly amylin candidate met-233i

Placebo-subtracted mean weight loss up to 8.4% at day 36 19-day observed half-life supports once-monthly dosing as monotherapy and  potential first-in-category monthly glp-1 + amylin combination well-tolerated with no safety signals company to host conference call and webcast today at 8:00 a.m. et new york, june 09, 2025 (globe newswire) -- metsera, inc. (nasdaq: mtsr), today announced positive topline data from the phase 1 clinical trial of met-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with metsera's fully-biased monthly glp-1 receptor agonist candidate, met-097i.
MTSR Ratings Summary
MTSR Quant Ranking